CLINICAL_TRIALS
trial_result
· 2017-01-11
Clinical Trial Update: Study of Phosphatidylinositol-3-kinase (PI3K) Inhibitor Idelalisib (GS-1101) in Waldenström Macroglobulinemia [Phase 2]
Summary
Phase 2 study of idelalisib in Waldenström macroglobulinemia was terminated, with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Dana-Farber Cancer Institute | Conditions: Waldenstrom's Macroglobulinemia | Phase 2 | Status: TERMINATED | Results posted: 2017-01-11